Binge Eating Liraglutide Intervention

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (146 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-10-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 37.9% (lowers risk) · Drug's FDA history
• Minimum age: 21 (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerscorediseaseheartdisorder
  Phrases that lowered it: foodtrialparticipantsreceiptblood pressure
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 3.1% (lowers risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Maximum age: 70 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 1 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated) NCT03158805 · started 2017 · scored riskier than 50% of active trials completed
• Daily Liraglutide for Nicotine Dependence NCT03712098 · started 2018 · scored riskier than 13% of active trials completed
• Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance NCT00781937 · started 2008 · scored riskier than 14% of active trials completed
• Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity NCT03523273 · started 2017 · scored riskier than 7% of active trials completed
• Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin NCT02963922 · started 2017 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.